Methods and compositions for correlating genetic markers with cancer risk
AssigneeWake Forest University Health Sciences
InventorsJianfeng Xu, Jielin Sun, Siqun Lilly Zheng, Zhuo Chen, Li Wang, Zheng Zhang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of assessing an individual subject's risk of developing different types of cancer, comprising calculating a genetic risk score (GRS) for the subject.
Claims18
A method of producing a personalized cancer risk report for a subject, comprising:
- a) determining, from a nucleic acid sample obtained from the subject, a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each locus of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele and wherein said plurality of biallelic polymorphic loci is a multiplicity, in any combination, of the single nucleotide polymorphisms in Table 1 (breast), Table 2 (lung), Table 3 (colorectal), Table 4 (prostate), Table 5 (glioma), Table 6 (neuroblastoma), Table 7 (chronic lymphocytic leukemia), Table 8 (pancreatic), Table 9 (non-Hodgkin lymphoma), Table 10 (bladder), Table 11 (renal) Table 12 (ovarian), Table 13 (melanoma), Table 14 (Hodgkin lymphoma), Table 15 (acute lymphocytic leukemia), Table 16 (thyroid), and/or Table 17 (testicular);
- b) calculating a genetic risk score (GRS) for the subject based on the genotype determined for said plurality of biallelic polymorphic loci of step (a);
- and
- c) producing a personalized cancer risk report for the subject based on the GRS calculated in step (b).
A method of identifying a subject as having an increased risk of developing breast cancer, lung cancer, colorectal cancer, prostate cancer, glioma, neuroblastoma, chronic lymphocytic leukemia, pancreatic cancer, non-Hodgkin lymphoma, bladder cancer, renal cancer, ovarian cancer, melanoma, Hodgkin lymphoma, acute lymphocytic leukemia, thyroid cancer and/or testicular cancer, comprising:
- a) determining, from a nucleic acid sample obtained from the subject, a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each locus of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele and wherein said plurality of biallelic polymorphic loci is a multiplicity, in any combination, of the single nucleotide polymorphisms in Table 1 (breast), Table 2 (lung), Table 3 (colorectal), Table 4 (prostate), Table 5 (glioma), Table 6 (neuroblastoma), Table 7 (chronic lymphocytic leukemia), Table 8 (pancreatic), Table 9 (non-Hodgkin lymphoma), Table 10 (bladder), Table 11 (renal) Table 12 (ovarian), Table 13 (melanoma), Table 14 (Hodgkin lymphoma), Table 15 (acute lymphocytic leukemia), Table 16 (thyroid), Table 17 (testicular);
- and
- b) calculating a genetic risk score (GRS) for the subject based on the genotype determined for each plurality of biallelic polymorphic loci in step (a), wherein a GRS of greater than 1.0 identifies the subject as having an increased risk of developing the type of cancer associated with said GRS of greater than 1.0, thereby identifying the subject as having an increased risk of developing breast cancer, lung cancer, colorectal cancer, prostate cancer, glioma, neuroblastoma, chronic lymphocytic leukemia, pancreatic cancer, non-Hodgkin lymphoma, bladder cancer, renal cancer, ovarian cancer, melanoma, Hodgkin lymphoma, acute lymphocytic leukemia, thyroid cancer and/or testicular cancer.
A kit comprising reagents and instructions for carrying out the method of 1.
Dependencies are inferred from the claim text.